Noveltreat to be available in five dose strengths of 0.25 mg/0.5 mL, 0.5 mg/0.5 mL, 1 mg/0.5 mL, 1.7 mg/0.75 mL and 2.4 ...

Sun Pharma receives DCGI approval to launch generic semaglutide injection, Noveltreat, for weight management in India.

Sun Pharma has received DCGI approval for generic semaglutide for weight management and will launch Noveltreat after the ...

DCGI approval to Sun Pharma comes amid an ongoing patent dispute with Novo Nordisk in the Delhi High Court. The case relates ...

Danish pharma major Novo Nordisk on Friday launched its blockbuster type 2 diabetes treatment injection Ozempic, globally popular for its weight-loss benefits. Ozempic is now available in India as ...

Sun Pharmaceutical Industries announced that it has received approval from the Drugs Controller General of India (DCGI) to manufacture and market a generic version of semaglutide injection.

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated for weight management as an adjunct to a reduced-calorie diet and increased physical activity.

Sun Pharma has received DCGI approval to launch Noveltreat, a generic semaglutide injection for chronic weight management in ...

Danish pharma major Novo Nordisk on Friday launched its blockbuster type 2 diabetes treatment injection Ozempic, globally popular for its weight-loss benefits. Ozempic is now available in India as ...

This form of rapid-acting inhaled insulin, recently introduced in India by the name Afrezza, is said to offer an important ...

The company has received approval from the Drugs Controller General of India (DCGI) to manufacture and market Semaglutide ...

New Delhi: Danish pharma major Novo Nordisk on Friday launched its blockbuster type 2 diabetes treatment injection Ozempic, globally popular for its weight-loss benefits. Ozempic is now available in ...